Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017136497) DETECTION AND TREATMENT OF IL-17 AND IL-13 RELATED CONDITIONS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/136497 International Application No.: PCT/US2017/016127
Publication Date: 10.08.2017 International Filing Date: 02.02.2017
IPC:
A61K 39/395 (2006.01) ,A61P 11/06 (2006.01) ,G01N 33/53 (2006.01) ,G01N 33/68 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
06
Antiasthmatics
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68
involving proteins, peptides or amino acids
Applicants:
THE CLEVELAND CLINIC FOUNDATION [US/US]; 9500 Euclid Ave Cleveland, Ohio 44195, US
Inventors:
LI, Xiaoxia; US
BULEK, Katarzyna; US
LIU, Caini; US
ARONICA, Mark; US
HONG, Liz; US
Agent:
BOND, Jason R.; US
Priority Data:
62/290,53503.02.2016US
Title (EN) DETECTION AND TREATMENT OF IL-17 AND IL-13 RELATED CONDITIONS
(FR) DÉTECTION ET TRAITEMENT DE PATHOLOGIES LIÉES À L’IL-17 ET À L’IL-13
Abstract:
(EN) Provided herein are compositions, systems, and methods for detecting and treating IL-17 and/or IL-13 related conditions, such as asthma, autoimmune diseases, and cancer. In some embodiments, methods, compositions, and systems are provided for detecting elevated protein or RNA levels of IL-17 (and/or IL-13) and a second marker selected from: SAA, LCN2, and YKL-40, and treating the subject with an IL-17 (or IL-13) inhibitor or IL-17 (or IL-13) receptor inhibitor. In other embodiments, methods, compositions, and systems are provided for detecting a biomarker in a sample from a subject that has been treated with an IL-17 (or IL-13) inhibitor or IL-17 (or IL-13) receptor inhibitor, where the biomarker is SAA, LCN2, or YKL-40, and where at least one action is performed, such as identifying elevated levels of the biomarker in the biological sample and treating the subject with an IL-17 (or IL-13) inhibitor and/or IL-17 (or IL-13) receptor inhibitor.
(FR) L’invention concerne des compositions, des systèmes et des procédés permettant la détection et le traitement de pathologies liées à l’IL-17 et/ou à l’IL-13, telles que l’asthme, les maladies auto-immunes, et le cancer. Selon certains modes de réalisation, l’invention concerne des procédés, des compositions et des systèmes permettant la détection de taux élevés en protéines ou en ARN pour l’IL-17 (et/ou l’IL-13) et d’un second marqueur choisi parmi : SAA, LCN2, et YKL-40, et le traitement du sujet au moyen d’un inhibiteur d’IL-17 (ou d’IL-13) ou d’un inhibiteur de récepteur d’IL-17 (ou d’IL-13). Selon d’autres modes de réalisation, l’invention concerne des procédés, des compositions, et des systèmes permettant la détection d’un biomarqueur dans un échantillon provenant d’un sujet ayant été traité au moyen d’un inhibiteur d’IL-17 (ou d’IL-13) ou d’un inhibiteur de récepteur d’IL-17 (ou d’IL-13), où le biomarqueur est SAA, LCN2, ou YKL-40, et où au moins une action est réalisée, telle qu’une identification de taux élevés du biomarqueur dans l’échantillon biologique et le traitement du sujet au moyen d’un inhibiteur d’IL-17 (ou d’IL-13) ou d’un inhibiteur de récepteur d’IL-17 (ou d’IL-13).
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
US20190033322